Stuart A. Arbuckle, EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 7,166 shares at $212.52 ($1.5M) on 2021-02-25, disclosed to the SEC on 2021-02-26.
Seasonal sale ($1.5M) by EVP, Chief Commercial Officer — this insider has traded VRTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $217.57 | 2,898 | $631K | 40.9% |
| 2 | $211.39 | 380 | $80K | 5.2% |
| 3 | $211.39 | 380 | $80K | 5.2% |
| 4 | $212.52 | 900 | $191K | 12.4% |
| 5 | $213.55 | 1,400 | $299K | 19.4% |
| 6 | $214.32 | 400 |
| $86K |
| 5.6% |
| 7 | $215.62 | 300 | $65K | 4.2% |
| 8 | $216.57 | 254 | $55K | 3.6% |
| 9 | $216.57 | 254 | $55K | 3.6% |
| Total | $215.16 avg | 7,166 | $1.5M | 100% |
| Filing → |
| VRTX | SELL | 2024-02-23 | $3.0M | — | Filing → |
| VRTX | SELL | 2024-02-21 | $4.0M | — | Filing → |
| VRTX | SELL | 2024-02-13 | $3.6M | — | Filing → |